Clearing the Deck for Eli Lilly

4/10/2026

Apr 10, 2026

∙ Paid

I made a move I don’t make often. I sold multiple positions and trimmed across the board, not because anything was wrong, but because something better showed up.

Eli Lilly (LLY) is trading under $940. Morgan Stanley just reiterated Buy with a $1,327 target. BofA has it at $1,294 Strong Buy. Guggenheim at $1,163 Strong Buy. Consensus across 18 analysts is $1,215 with 89% rating it Buy or Strong Buy.

Four straight quarters of earnings beats. 10.6%, 12.68%, 17.79%, 8.33%. Next report is April 30.

The FDA just approved Foundayo, the oral version of the GLP-1 franchise. Amazon Pharmacy is already stocking it. Zepbound and Mounjaro are printing money in injection form, and now Lilly has a pill for the massive patient population that doesn’t want needles. The cardiometabolic revenue segment went from $3B to over $21B in three years. That curve isn’t flattening.

Continue reading this post for free, courtesy of The M&A Hunter.

Or purchase a paid subscription.